
FDA approves Pentixapharm’s dual theranostic INDs
The US Food and Drug Administration (FDA) has approved a clinical study of Pentixapharm’s CXCR4-targeted theranostic programme in haemato-oncology, following a 30-day safety review of two Investigational New Drug (IND) applications. The two IND submissions support the single PENTHERA Phase I/II protocol, which evaluates the combined use… Read More
